Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds

References

• Kitchin K T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems and methylated arsenic metabolites. Toxicol Appl Pharmacol 2001; 172: 249–261
   PubMed Web of Science ®Google Scholar
• Sun H D, Ma L, Hu X C, Zhang T D. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin Western Med 1992; 12: 170–172
   Google Scholar
• Chen G Q, Zhu J, Shi X G, Ni J N, Zhong H J, Si G Y, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052–1061
   PubMed Web of Science ®Google Scholar
• Chen G Q, Shi X G, Tang W. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–3353
   PubMed Web of Science ®Google Scholar
• Warrell R P, Jr, de The H, Wang Z Y, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhao L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel M, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi P P, Donti E, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10–25
   PubMed Web of Science ®Google Scholar
• Frankel S R, Eardley A, Lauwers G, Weiss M, Warrell R P, Jr. The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292–296
   PubMed Web of Science ®Google Scholar
• Delva L, Comic M, Balitrand N, Guidez F, Miclea J M, Delmer A, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro all-trans retinoic acid sensitivity and cellular retinoic acid-binding protein levels in leukemic cell. Blood 1993; 82: 2175–2181
   PubMed Web of Science ®Google Scholar
• Warrell R P, Jr. Retinoid resistance in acute promyelocytic leukemia. New mechanisms, strategies and implications. Blood 1993; 82: 1949–1953
   PubMed Web of Science ®Google Scholar
• Zhang T C, Schmitt M T, Mumford J L. Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 2003; 24: 1811–1817
   PubMed Web of Science ®Google Scholar
• Sells S F, Wood D P, Joshi-Barve S S, Muthukumar S, Jacob R J, Crist S A, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994; 5: 457–466
   PubMedGoogle Scholar
• Sells S F, Han S S, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 1997; 17: 3823–3832
   PubMed Web of Science ®Google Scholar
• Qiu G, Ahmed M, Sells S F, Mohiuddin M, Weinstein M H, Rangnekar V M. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumours consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1997; 18: 623–631
   Web of Science ®Google Scholar
• Diaz-Meco M T, Municio M M, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 1996; 86: 777–786
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S, Reed J C. ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. Mol Cell Biol 2003; 23: 6174–6186
   PubMed Web of Science ®Google Scholar
• Karakas T, Miething C C, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L. The co expression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002; 16: 846–854
   PubMed Web of Science ®Google Scholar
• Glienke W, Seil I, Bauer N, Bergmann L. Small interfering RNA-mediated gene silencing of WT1 in leukemia cell lines. Proc Am Soc Clin Oncol (ASCO) 2005, Abstract #3199
   Web of Science ®Google Scholar
• Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Soignet S L, Maslak P, Wang Z G, Jhanwar S, Calleja E, Dardashti D, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348
   PubMed Web of Science ®Google Scholar
• Puccetti E, Güller S, Orleth A, Brüggenolte N, Hoelzer D, Ottmann O G, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000; 60: 3409–3413
   PubMed Web of Science ®Google Scholar
• Boehrer S, Chow K U, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, et al. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2001; 2: 103–107
   PubMedGoogle Scholar
• Chou W C, Hawkins A L, Barrett J F, Griffin C A, Dang C. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001; 108: 1541–1547
   PubMed Web of Science ®Google Scholar
• Li J, Liu S X. Changes of telomerase activity and hTERT mRNA expression in the process of HL-60 cells induced by arsenic sulphide. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003; 19: 595–597
   PubMedGoogle Scholar
• Kyo S. Sp1 cooperate with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2001; 28: 669–677
   Web of Science ®Google Scholar
• Wu K J. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220–224
   PubMed Web of Science ®Google Scholar
• Bergmann L, Miething C C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D. High levels of Wilms' tumour gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217–1225
   PubMed Web of Science ®Google Scholar
• Bergmann L, Maurer U, Weidmann E. Wilms' tumor gene expression in acute myeloid leukemias. Lymphoma 1997; 25: 435–443
   PubMed Web of Science ®Google Scholar
• Savli H, Sirma S, Nagy B, Aktan M, Dincol G, Ozbek U. Real-time PCR analysis of the apoptosis related genes in ATRA treated APL t(15;17) patients. Exp Mol Med 2003; 35: 454–459
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yamada O, Yanagisawa T, Fujisawa K, Eto Y, Yamada H. Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic treated with all-trans retinoic acid. Ped Blood Cancer 2006; 46: 506–511
   PubMed Web of Science ®Google Scholar
• Chou W C, Chen H Y, Yu S L, Cheng L, Yang P C, Dang C V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005; 106: 304–310
   PubMed Web of Science ®Google Scholar
• Cohen H T, Bossone S A, Zhu G, McDonald G A, Sukhatme V P. Sp1 is a critical regulator of the Wilms' tumor-1 gene. J Biol Chem 1997; 272: 2901–2913
   PubMed Web of Science ®Google Scholar
• Hübinger G, Schmid M, Linortner S, Manegold A, Bergmann L, Maurer U. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Haematol 2001; 29: 1226–1235
   PubMed Web of Science ®Google Scholar
• Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, et al. Growth inhibition of human leukaemic cells by wt1 antisense oligonucleotides: implication for the involvement of WT-1 in leukemogenesis. Blood 1996; 87: 2878–2884
   PubMed Web of Science ®Google Scholar
• Algar E M, Khromykh T, Smith S I, Blackburn D M, Bryson G J, Smith P J. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 1996; 12: 1005–1014
   PubMed Web of Science ®Google Scholar
• Yamagami T, Ogawa H, Tamaki H, Oji Y, Soma T, Oka Y, et al. Suppression of Wilms' tumour gene (WT1) expression induces G2/M arrest in leukaemic cells. Leuk Res 1998; 22: 383–384
   PubMed Web of Science ®Google Scholar